(Q28246333)

English

Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer

scientific article (publication date: 2015)

In more languages

Statements

scholarly article

0 references

Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Nigel Fleeman

1

0 references

Adrian Bagust

2

0 references

Sophie Beale

3

0 references

Kerry Dwan

4

0 references

Rumona Dickson

5

0 references

Chris Proudlove

6

0 references

Yenal Dundar

7

0 references

language of work or name

0 references

publication date

January 2015

0 references

PharmacoEconomics

0 references

33

0 references

1

0 references

13-23

0 references

Survival differences among women with de novo stage IV and relapsed breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

HER2 as a prognostic factor in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Indirect comparisons of competing interventions

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Health state utilities for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0206-2

21 January 2018

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://pubmed.ncbi.nlm.nih.gov/25138171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in cancer incidence and mortality in England and Wales and a comparison of cancer deaths in the major developed countries by age and sex 1979-2002 in context of GDP expenditure on health

1 reference

https://pubmed.ncbi.nlm.nih.gov/25138171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK

1 reference

https://pubmed.ncbi.nlm.nih.gov/25138171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2/neu amplification predicts poor survival in node-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25138171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://pubmed.ncbi.nlm.nih.gov/25138171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40273-014-0206-2

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28246333&oldid=2177537844"